What Avastin treats: main uses and benefits

Avastin (bevacizumab) is a prescription medicine used to help manage the progression of certain advanced or metastatic solid tumors. The treatment is indicated for specific types of colorectal, non-small cell lung, kidney, ovarian, and cervical cancers. It is commonly utilized in clinical scenarios alongside standard chemotherapy regimens to help delay disease progression and provide supportive symptom management. The primary benefit patients may receive is the potential to help control the growth and spread of these malignant conditions. Avastin is also approved for treating recurrent glioblastoma, a type of brain tumor.

Quick Fact: Treatment for Advanced and Metastatic Solid Tumors

Who Can and Cannot Use Avastin (Bevacizumab)?

Eligibility for Avastin (bevacizumab) is strictly defined by regulatory guidelines, focusing on absolute exclusions and specific patient conditions.

Populations for Whom Use is Contraindicated

Avastin is contraindicated and must not be used in:

• Pregnant women, due to the potential for fetal harm.
• Patients with known hypersensitivity to bevacizumab, any excipients, or Chinese Hamster Ovary (CHO) cell products.

Restricted and Age-Related Eligibility

Category	Regulatory Status
Pediatric Population (<18 years)	Safety and efficacy have not been established; use is not recommended.
Geriatric Population (>65 years)	Requires caution due to an increased risk of arterial thromboembolic events.
Renal/Hepatic Impairment	Safety and efficacy have not been studied in these patient groups.

Conditions Requiring Discontinuation or Restriction

Treatment must be permanently discontinued if a patient develops a gastrointestinal perforation, a fistula involving an internal organ, or a hypertensive crisis. Additionally, Avastin must not be initiated for at least 28 days following major surgery until the surgical wound is fully healed. Women of childbearing potential are required to use effective contraception during and for six months after the treatment period.

Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns and restrictions for Bevacizumab (Avastin), primarily concerning additive toxicities and administration requirements.

---

Pharmacodynamic and Procedural Interactions

The most serious documented interaction risk involves co-administration with Sunitinib, a combination associated with an increased hazard for Microangiopathic Hemolytic Anemia (MAHA) and microvessel lesions. Other pharmacodynamic risks include the potential for additive hypertension or tachycardia when combined with agents like Solriamfetol. The label also notes an interaction with Live Vaccines, which may be less effective or pose an increased risk of causing illness due to potential immunological interference.

Procedural Timing Rules:

To manage the officially recognized risk of impaired wound healing, Bevacizumab must be withheld for at least 28 days prior to elective surgery and should not be initiated for at least 28 days following major surgery or until the surgical site is fully healed.

---

Administration and Pharmacokinetic Notes

A critical administration constraint is the strict incompatibility with Dextrose Solution (5% Dextrose); the drug must not be mixed with this fluid. Regarding other medicines, a pharmacokinetic interaction is documented where co-administration results in an increase of approximately 33% in the plasma levels of Irinotecan's active metabolite (SN-38).

How Avastin Works

The mechanism of Bevacizumab (Avastin) operates by highly selective engagement with the growth factor signaling system required for vascular development, resulting in the systemic suppression of blood vessel support.

---

️ Molecular Neutralization of VEGF-A

The drug's primary action is the neutralizing inhibition of the Vascular Endothelial Growth Factor A (VEGF-A) ligand. As a monoclonal antibody, Bevacizumab physically binds to VEGF-A in the circulation, preventing this crucial growth signal from reaching its receptors (VEGFR-1 and VEGFR-2) on the endothelial cells. This initial molecular blockade halts the signal transduction cascade that otherwise drives rapid vascular growth.

---

Disruption of Angiogenesis and Vascular Structure

This molecular blockade results in the collapse and regression of existing, unstable microvasculature, alongside the complete suppression of new blood vessel formation (anti-angiogenesis). The resulting physiological effect is the reduction of oxygen and nutrient supply to the target tissue, thereby influencing the rate of cell proliferation. Furthermore, the mechanism temporarily drives the normalization of surviving vessels, reducing their leakiness and modifying structure.

---

Functional Facilitation of Systemic Therapy

The mechanism of vascular normalization establishes a specific functional characteristic to the resulting systemic physiological effect. By transiently reducing the chaotic structure and high pressure of the blood vessels, the drug facilitates more organized blood flow. This physiological adjustment facilitates the systemic delivery and distribution of other co-administered therapeutic agents into the affected tissue.

How to Use Avastin (Bevacizumab)

The usage of Avastin (bevacizumab) follows specific guidelines related to its route, dose, and administration schedule.

---

Administration Overview

Feature	Official Administration Guidelines
Route of Administration	Administered exclusively as an Intravenous (IV) Infusion. It must never be given as a rapid IV push or bolus.
Dosing Schedule	Dosing is calculated by body weight (milligrams per kilogram or mg/kg) and is tailored to the specific indication. Typical doses range from 5 mg/kg to 15 mg/kg, administered in cycles.
Frequency Pattern	Treatment is given on an intermittent schedule, typically once every two or three weeks, in conjunction with a specific chemotherapy regimen.
Duration of Use	The medicine is generally continued until the underlying disease progresses or if the patient experiences unacceptable toxicity.

---

Procedural Requirements and Conditions

Avastin is a sterile concentrate for solution for infusion that requires preparation. The concentrate must be diluted in 100 mL of 0.9% Sodium Chloride Injection, USP, prior to administration. It must not be mixed with dextrose (glucose) solutions due to incompatibility.

Infusion delivery begins with an initial 90 minute infusion, which may be subsequently shortened to 60 minutes and then 30 minutes if the preceding infusion was well tolerated. All infusions must occur under the supervision of a physician experienced in antineoplastic therapy.

For older adults (aged 65 years and over), no specific dose adjustment is typically required. Regarding surgical constraints, Avastin must be withheld for at least 28 days prior to elective surgery and should not be resumed until the surgical wound is fully healed.

Research Evidence / Overview of Studies for Avastin (Bevacizumab)

Research Evidence for Metastatic Colorectal Cancer

Bevacizumab was evaluated in major, international Randomized Controlled Trials (RCTs) involving adults with metastatic colorectal cancer (mCRC). These studies were conducted to assess the drug when added to standard chemotherapy. The research primarily examined key long-term health metrics such as Overall Survival (OS) and Progression-Free Survival (PFS).

Through systematic reviews, data show patterns related to measurements of Progression-Free Survival (PFS) across many different study populations and chemotherapy combinations. In these studies, research highlights changes measured during the study period for both OS and PFS when the therapy was observed in combination with standard chemotherapy, compared to chemotherapy alone. Research is ongoing to better understand the role of patient biomarkers in the context of treatment outcomes.

Research Evidence for Non-Small Cell Lung Cancer (non-squamous)

The evidence for the use of bevacizumab in advanced non-small cell lung cancer (nsNSCLC) is primarily based on pivotal Phase III Randomized Controlled Trials (RCTs). These studies examined adults with unresectable or metastatic disease in the initial treatment setting, specifically focusing on those with non-squamous tumor types. Outcomes monitored included Overall Survival (OS) and Progression-Free Survival (PFS).

In the key trials, studies monitored measurements of OS and PFS for the group receiving bevacizumab combined with platinum-based chemotherapy and compared them to chemotherapy alone. The findings describe group patterns that were included in the regulatory review for its use in this specific type of lung cancer. No extensive research was conducted on patients with squamous cell lung cancer; results apply only to the populations studied.

Research Evidence for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The use was evaluated in a series of major international Phase III Randomized Controlled Trials (RCTs) for advanced ovarian, fallopian tube, and primary peritoneal cancers. The studies primarily monitored Progression-Free Survival (PFS) and Overall Survival (OS). Multiple large trials described a consistent pattern of Progression-Free Survival (PFS) measurements. However, findings were mixed regarding Overall Survival (OS) measurements across different trials and recurrence settings. There is limited information for long-term outcomes that would clarify which specific subgroups may reflect the observed OS patterns.

Evidence Gaps and Areas of Scientific Uncertainty

While substantial evidence exists from RCTs, several research gaps and uncertainties remain. Data for certain groups remain insufficient, particularly for pediatric populations, as the drug was studied for adults. Subgroup findings are uncertain in specific areas, such as the full analysis of subsequent therapies on final OS measurements. The evidence quality varies across studies for recurrent glioblastoma, where certainty remains low for long-term survival measures. The research provides context, and the findings reflect the specific conditions under which they were conducted.

Key Studies & References

1. NICE Guideline NG122: Colorectal cancer: diagnosis and management
2. NICE Guideline NG121: Non-small-cell lung cancer: diagnosis and management

Common questions about Avastin (FAQ)

Q: What is Avastin (bevacizumab)?

Avastin is a prescription medicine used to treat several types of cancer. Its active ingredient is bevacizumab, which is a type of protein known as a monoclonal antibody.

Q: How does Avastin work?

Avastin works by targeting a protein called Vascular Endothelial Growth Factor (VEGF). VEGF plays a key role in forming new blood vessels, a process called angiogenesis, which tumors need to grow and spread.

By binding to VEGF, Avastin helps prevent the formation of new blood vessels that feed the tumor. This action is intended to slow tumor growth and may cause some tumors to shrink.

Q: What types of cancer is Avastin used to treat?

Avastin is approved for use in combination with other chemotherapy drugs to treat several cancers, which may include:

• Metastatic colorectal cancer (cancer that has spread from the colon or rectum).
• Non-small cell lung cancer (a type of lung cancer).
• Glioblastoma (a type of brain tumor).
• Metastatic renal cell carcinoma (kidney cancer that has spread).
• Cervical cancer.
• Epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Q: How is Avastin given?

Avastin is given as an intravenous (IV) infusion (a drip into a vein) by a healthcare professional. It is typically administered in a clinic or hospital setting.

Q: What are the potential side effects of Avastin?

Avastin can cause serious side effects, and some are more common than others. Common side effects may include:

• High blood pressure (hypertension).
• Tiredness (fatigue).
• Nosebleeds (epistaxis).
• Headache.
• Protein in the urine (proteinuria).
• Diarrhea.
• Back pain.

More serious, but less common, side effects can include severe bleeding, heart problems, and blood clots. Patients should report any concerning symptoms to their healthcare provider.

How to Store and Dispose of Avastin?

The storage and disposal of Avastin (bevacizumab) are strictly governed by regulatory requirements to ensure its stability and safety. The unopened vial must be stored in a refrigerator at 2 C to 8 C and kept in the original carton to protect it from light. It is crucial not to freeze the product and not to shake the vial. Because the concentrate is preservative-free, preparation must be performed using aseptic technique and diluted exclusively in 0.9% Sodium Chloride solution.

Once prepared, the diluted solution is stable for up to 8 hours when refrigerated. As the vial is single-use, any unused portion of the concentrate remaining after preparation must be discarded immediately in accordance with local pharmaceutical waste disposal procedures.